The type 1 pill that helps while you take it: baricitinib’s honest update
At EASD 2025 (reported 19 September 2025) a follow-up of the BANDIT trial found baricitinib’s benefit faded once the daily pill was stopped.
Baricitinib is one of the more interesting names in Type 1 research, partly because it is not exotic: it is an existing, affordable tablet already used for other conditions. The appeal is that in a trial it helped protect the body’s own insulin-making for a while after diagnosis, by calming the immune attack behind Type 1. The honest update from 2025 is the catch: when people stopped taking it, the benefit faded and their diabetes carried on progressing. So it looks like a help while you take it, not a one-off fix, and it is still being studied.
- Baricitinib calms part of the immune system, and in Type 1 the idea is to slow the immune attack on the insulin-making cells.
- In the BANDIT trial, people who had recently been diagnosed kept more of their own insulin production for a time while taking the daily tablet.
- The 2025 follow-up found that once the tablet was stopped, that protection did not hold and the condition progressed.
- Because it is a cheap, existing medicine, a version that worked would matter a lot to the NHS, which is part of why it is watched closely.
- This is trial research, not an approved Type 1 treatment, so it is not something you can be prescribed for Type 1 today.
What the 2025 update actually said
At a major diabetes research meeting in September 2025, researchers reported a follow-up from the BANDIT trial. BANDIT had tested baricitinib, taken as a daily tablet, in people recently diagnosed with Type 1, to see whether it could protect the insulin-making cells the immune system was still attacking. Early on, the results looked promising: people on the tablet held on to more of their own insulin production than those who were not.
The follow-up tempered that. Once baricitinib was stopped, participants’ diabetes progressed, which suggests the protection depended on staying on the medicine rather than being a lasting reset. That is an important and honest finding, even though it is a more modest headline than the early excitement.
Promising, but genuinely unfinished
It is worth being clear about what this is and is not. Protecting some of your own insulin production can help, because a body still making a little of its own insulin often has steadier glucose and sometimes fewer severe lows. That is a real prize. But this is not a cure, and it is not a delay drug for people found before diagnosis. It is an idea about ongoing treatment that now needs more research to know whether long-term use is safe and worth it.
This audience has heard a decade of hopeful headlines that went quiet, so the fair way to file baricitinib is neither breakthrough nor bust. It is one honest step: an existing, cheap medicine that does something measurable while taken, with real questions still open. If it does reach people with Type 1, that is years away and depends on further trials and approval, not months.